Showing results (1-10 of 74) with videos related to
Sort By:
Pageof 8
Translational Lung Cancer Research|February 11, 2021
Neoadjuvant treatment of stage IIIA-N2 in EGFR-Mutant/ALK-rearranged non-small cell lung cancerRoxana Reyes, Noemi ReguartFuture Oncology (London, England)|January 29, 2015
Common EGFR-mutated subgroups (Del19/L858R) in advanced non-small-cell lung cancer: chasing better outcomes with tyrosine kinase inhibitorsNoemi Reguart, Jordi RemonJournal of Thoracic Disease|June 29, 2018
Immune-related adverse events with immune checkpoint inhibitors in thoracic malignancies: focusing on non-small cell lung cancer patientsJordi Remon, Laura Mezquita, Jesús Corral, et al.Lung Cancer (Amsterdam, Netherlands)|November 26, 2002
DNA repair and cisplatin resistance in non-small-cell lung cancerRafael Rosell, Reginald V N Lord, Miquel Taron, et al.Current Opinion in Pharmacology|June 13, 2006
Predicting the outcome of chemotherapy for lung cancerRafael Rosell, Fabiana Cecere, Mariacarmela Santarpia, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 26, 2006
Epidermal growth factor receptor activation: how exon 19 and 21 mutations changed our understanding of the pathwayRafael Rosell, Miquel Taron, Noemi Reguart, et al.American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|June 2, 2026
Updates in Small Cell Lung Cancer Treatment: No Longer Too Small to Ignore-A Review of Recent Therapeutic AdvancesYajur Arya, Patrick Dyer, Fiona Hegi-Johnson, et al.Future Oncology (London, England)|March 25, 2006
The role of Wnt signaling in cancer and stem cellsNoemi Reguart, Biao He, Miquel Taron, et al.Oncotargets and Therapy|May 16, 2017
Tyrosine kinase inhibitor combination therapy in first-line treatment of non-small-cell lung cancer: systematic review and network meta-analysisSarah Batson, Stephen A Mitchell, Ricarda Windisch, et al.Current Opinion in Oncology|February 8, 2006
Treatment of non-small-cell lung cancer and pharmacogenomics: where we are and where we are goingRafael Rosell, Mauricio Cuello, Fabiana Cecere, et al.Pageof 8